Reports Q4 revenue $55.56M, consensus $52.72M. “2023 was characterized by record revenue growth for HEPLISAV-B, and the achievement of becoming the market share leader in the two largest growth segments, demonstrating important progress toward our goal of establishing HEPLISAV-B as the leading vaccine in the U.S. adult hepatitis B vaccine market,” said Ryan Spencer, CEO. “We expect 2024 to be an important year in building a vaccine portfolio of best-in-class products, including further growing the HEPLISAV-B brand as well as advancing our pipeline programs into clinical trial initiations and data readouts. Importantly, our strong financial position provides us with the optionality to continue to build value across our business, including through investing to drive the HEPLISAV-B market opportunity, advancing and expanding our R&D efforts, and pursuing strategic opportunities to accelerate our growth.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DVAX:
- Qualcomm downgraded, Cigna upgraded: Wall Street’s top analyst calls
- Dynavax initiated with a Neutral at Goldman Sachs
- Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Highlights
- Dynavax sees FY23 HEPLISAV-B vaccine net product revenue about $213M
- Dynavax sees Q4 HEPLISAV-B vaccine net product revenue about $51M